China's First Home-Developed Anti-Cancer Drug Deemed to Hit the Market by Year-End
Dou Shicong
DATE:  Jun 29 2018
/ SOURCE:  Yicai
China's First Home-Developed Anti-Cancer Drug Deemed to Hit the Market by Year-End China's First Home-Developed Anti-Cancer Drug Deemed to Hit the Market by Year-End

(Yicai Global) June 29 -- Hutchison China MediTech has finished relevant testing of the first anti-cancer drug which was invented by a Chinese scientist and produced by a Chinese company with an aim to bring the product to the domestic market by the end of this year.

Users of fruquintinib oral medicine survived 9.3 months longer, which so far is the longest time that can be achieved among colorectal cancer patients globally, the Shanghai-based drugmaker said in a statement. The London-listed firm's parent is CK Hutchison that is controlled by Hong Kong billionaire Li Ka-shing's son.

Some 1.4 million people become ill with colorectal cancer every year, and some 694,000 die from it each year. In China, about 376,000 new cases of colorectal cancer occur yearly.

Hutchison China MediTech has submitted a new drug listing application to the China Food and Drug Administration which has granted a priority review status to it.

Some 28 research institutions, such as the Shanghai Oriental Hospital that is affiliated with Tongji University and the Fudan University Shanghai Cancer Center have tested the product.

Editor: Emmi Laine

Follow Yicai Global on
Keywords:   Anti-Cancer Drug,Hutchison China MediTech,Fruquintinib,Colorectal Cancer